Compare $ACXP vs $SKYE | Chartloom

Compare

$ACXP vs $SKYE

Acurx Pharmaceuticals Inc · Skye Bioscience Inc

ACXP

Acurx Pharmaceuticals Inc

SKYE

Skye Bioscience Inc

Compare $ACXP vs $SKYE

Comparing Acurx Pharmaceuticals Inc and Skye Bioscience Inc

ACXPAcurx Pharmaceuticals Inc

SKYESkye Bioscience Inc

ACXPAcurx Pharmaceuticals Inc

Market cap

$5M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-54.0%

52W performance

-84.3%

FCF yield

-113.2%

SKYESkye Bioscience Inc

Market cap

$59M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-75.9%

52W performance

-87.7%

FCF yield

-65.4%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ACXP

SKYE

Detailed metrics comparison

ACXP

Acurx Pharmaceuticals Inc

SKYE

Skye Bioscience Inc

Market Cap

ACXP$5M

SKYE$59M

Enterprise Value

ACXP$-5M

SKYE$51M

Price

ACXP$1.27

SKYE$1.69

P/E Ratio

ACXPN/A

SKYEN/A

P/S Ratio

ACXP0.00x

SKYE26.57x

EV/Sales

ACXP0.00x

SKYE0.00x

EV/EBITDA

ACXP0.00x

SKYE0.00x

P/B Ratio

ACXP0.87x

SKYE0.83x

P/FCF Ratio

ACXPN/A

SKYEN/A

EV/FCF

ACXP0.84x

SKYE-1.31x

PEG Ratio

ACXPN/A

SKYEN/A

Forward P/E (NTM)

ACXPN/A

SKYEN/A

Forward P/S (NTM)

ACXPN/A

SKYEN/A

Revenue (TTM)

ACXP$0

SKYE$0

Revenue Growth (YoY)

ACXPN/A

SKYEN/A

Forward Rev Growth

ACXP40.7%

SKYE307.4%

Gross Margin (TTM)

ACXP0.0%

SKYE39.3%

Operating Margin (TTM)

ACXP0.0%

SKYE0.0%

EBITDA Margin (TTM)

ACXP0.0%

SKYE0.0%

Net Margin (TTM)

ACXP0.0%

SKYE0.0%

FCF Margin (TTM)

ACXPN/A

SKYEN/A

Net Income (TTM)

ACXP$-8M

SKYE$-50M

FCF (TTM)

ACXP$-6M

SKYE$-39M

EPS (TTM)

ACXP-$1.76

SKYE-$10.18

ROE (TTM)

ACXP-12474.0%

SKYE-21727.0%

ROA (TTM)

ACXP-8749.0%

SKYE-20179.0%

ROIC (TTM)

ACXP-12474.0%

SKYE-21675.0%

Cash

ACXP$11M

SKYE$9M

Debt

ACXP$0

SKYE$143K

Net Cash/Debt

ACXP$11M

SKYE$8M

Current Ratio (TTM)

ACXP3.88x

SKYE0.95x

Quick Ratio (TTM)

ACXP3.80x

SKYE0.91x

Debt/Equity (TTM)

ACXP0.00x

SKYE0.03x

Debt/Assets (TTM)

ACXP0.0%

SKYE0.0%

Interest Coverage (TTM)

ACXPN/A

SKYEN/A

Net Debt/EBITDA (TTM)

ACXP0.00x

SKYE0.00x

Beta

ACXP-2.14

SKYE3.13

52W Performance

ACXP-84.3%

SKYE-87.7%

YTD Performance

ACXP-54.0%

SKYE-75.9%

% from 52W High

ACXP-84.4%

SKYE-88.0%

% from 52W Low

ACXP3.3%

SKYE12.7%

Asset Turnover (TTM)

ACXP0.00x

SKYE1.93x

FCF Yield (TTM)

ACXP-113.2%

SKYE-65.4%

Earnings Yield (TTM)

ACXP-137.5%

SKYE-85.0%

Dividend Yield (TTM)

ACXPN/A

SKYEN/A

Rule of 40

ACXP0.0

SKYE0.0

EV/GP/RG

ACXPN/A

SKYEN/A

Ticker research

View ACXP research View SKYE research

Metric	ACXP Acurx Pharmaceuticals Inc	SKYE Skye Bioscience Inc
Market & Valuation
Market Cap	$5M	$59M
Enterprise Value	$-5M	$51M
Price	$1.27	$1.69
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	26.57x
EV/Sales	0.00x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.87x	0.83x
P/FCF Ratio	N/A	N/A
EV/FCF	0.84x	-1.31x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	40.7%	307.4%
Profitability
Gross Margin (TTM)	0.0%	39.3%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-8M	$-50M
FCF (TTM)	$-6M	$-39M
EPS (TTM)	-$1.76	-$10.18
ROE (TTM)	-12474.0%	-21727.0%
ROA (TTM)	-8749.0%	-20179.0%
ROIC (TTM)	-12474.0%	-21675.0%
Financial Health
Cash	$11M	$9M
Debt	$0	$143K
Net Cash/Debt	$11M	$8M
Current Ratio (TTM)	3.88x	0.95x
Quick Ratio (TTM)	3.80x	0.91x
Debt/Equity (TTM)	0.00x	0.03x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-2.14	3.13
52W Performance	-84.3%	-87.7%
YTD Performance	-54.0%	-75.9%
% from 52W High	-84.4%	-88.0%
% from 52W Low	3.3%	12.7%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	1.93x
FCF Yield (TTM)	-113.2%	-65.4%
Earnings Yield (TTM)	-137.5%	-85.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View ACXP research	View SKYE research

Valuation

P/S Ratio

ACXP

0.00x

SKYE

26.57x

EV/FCF

SKYE

-1.31x

ACXP

0.84x

Growth & revenue

Forward Revenue Growth

SKYE

307.4%

ACXP

40.7%

Profitability & performance

Gross Margin

SKYE

39.3%

ACXP

0.0%

ROE

ACXP

-12474.0%

SKYE

-21727.0%

FCF Yield %

SKYE

-65.4%

ACXP

-113.2%

52-Week Performance

ACXP

-84.3%

SKYE

-87.7%

Detailed metrics comparison

ACXP

Acurx Pharmaceuticals Inc

SKYE

Skye Bioscience Inc

Market Cap

ACXP$5M

SKYE$59M

Enterprise Value

ACXP$-5M

SKYE$51M

Price

ACXP$1.27

SKYE$1.69

P/E Ratio

ACXPN/A

SKYEN/A

P/S Ratio

ACXP0.00x

SKYE26.57x

EV/Sales

ACXP0.00x

SKYE0.00x

EV/EBITDA

ACXP0.00x

SKYE0.00x

P/B Ratio

ACXP0.87x

SKYE0.83x

P/FCF Ratio

ACXPN/A

SKYEN/A

EV/FCF

ACXP0.84x

SKYE-1.31x

PEG Ratio

ACXPN/A

SKYEN/A

Forward P/E (NTM)

ACXPN/A

SKYEN/A

Forward P/S (NTM)

ACXPN/A

SKYEN/A

Revenue (TTM)

ACXP$0

SKYE$0

Revenue Growth (YoY)

ACXPN/A

SKYEN/A

Forward Rev Growth

ACXP40.7%

SKYE307.4%

Gross Margin (TTM)

ACXP0.0%

SKYE39.3%

Operating Margin (TTM)

ACXP0.0%

SKYE0.0%

EBITDA Margin (TTM)

ACXP0.0%

SKYE0.0%

Net Margin (TTM)

ACXP0.0%

SKYE0.0%

FCF Margin (TTM)

ACXPN/A

SKYEN/A

Net Income (TTM)

ACXP$-8M

SKYE$-50M

FCF (TTM)

ACXP$-6M

SKYE$-39M

EPS (TTM)

ACXP-$1.76

SKYE-$10.18

ROE (TTM)

ACXP-12474.0%

SKYE-21727.0%

ROA (TTM)

ACXP-8749.0%

SKYE-20179.0%

ROIC (TTM)

ACXP-12474.0%

SKYE-21675.0%

Cash

ACXP$11M

SKYE$9M

Debt

ACXP$0

SKYE$143K

Net Cash/Debt

ACXP$11M

SKYE$8M

Current Ratio (TTM)

ACXP3.88x

SKYE0.95x

Quick Ratio (TTM)

ACXP3.80x

SKYE0.91x

Debt/Equity (TTM)

ACXP0.00x

SKYE0.03x

Debt/Assets (TTM)

ACXP0.0%

SKYE0.0%

Interest Coverage (TTM)

ACXPN/A

SKYEN/A

Net Debt/EBITDA (TTM)

ACXP0.00x

SKYE0.00x

Beta

ACXP-2.14

SKYE3.13

52W Performance

ACXP-84.3%

SKYE-87.7%

YTD Performance

ACXP-54.0%

SKYE-75.9%

% from 52W High

ACXP-84.4%

SKYE-88.0%

% from 52W Low

ACXP3.3%

SKYE12.7%

Asset Turnover (TTM)

ACXP0.00x

SKYE1.93x

FCF Yield (TTM)

ACXP-113.2%

SKYE-65.4%

Earnings Yield (TTM)

ACXP-137.5%

SKYE-85.0%

Dividend Yield (TTM)

ACXPN/A

SKYEN/A

Rule of 40

ACXP0.0

SKYE0.0

EV/GP/RG

ACXPN/A

SKYEN/A

Ticker research

View ACXP research View SKYE research

Metric	ACXP Acurx Pharmaceuticals Inc	SKYE Skye Bioscience Inc
Market & Valuation
Market Cap	$5M	$59M
Enterprise Value	$-5M	$51M
Price	$1.27	$1.69
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	26.57x
EV/Sales	0.00x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.87x	0.83x
P/FCF Ratio	N/A	N/A
EV/FCF	0.84x	-1.31x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	40.7%	307.4%
Profitability
Gross Margin (TTM)	0.0%	39.3%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-8M	$-50M
FCF (TTM)	$-6M	$-39M
EPS (TTM)	-$1.76	-$10.18
ROE (TTM)	-12474.0%	-21727.0%
ROA (TTM)	-8749.0%	-20179.0%
ROIC (TTM)	-12474.0%	-21675.0%
Financial Health
Cash	$11M	$9M
Debt	$0	$143K
Net Cash/Debt	$11M	$8M
Current Ratio (TTM)	3.88x	0.95x
Quick Ratio (TTM)	3.80x	0.91x
Debt/Equity (TTM)	0.00x	0.03x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-2.14	3.13
52W Performance	-84.3%	-87.7%
YTD Performance	-54.0%	-75.9%
% from 52W High	-84.4%	-88.0%
% from 52W Low	3.3%	12.7%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	1.93x
FCF Yield (TTM)	-113.2%	-65.4%
Earnings Yield (TTM)	-137.5%	-85.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View ACXP research	View SKYE research